



## London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias

June 24, 2008

Installation of Stereotaxis Niobe(R) and Odyssey(TM) Systems Further Royal Brompton and Harefield NHS Trust's Leadership Role in the Treatment of Complex

### Heart Conditions

ST. LOUIS, June 24 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced that British Prime Minister Gordon Brown presided today over a ceremony unveiling the new state of the art electrophysiology lab at Royal Brompton Hospital in London. The new lab features Stereotaxis Niobe Magnetic Navigation and Odyssey Network systems, which in combination can provide unsurpassed safety, efficiency and clinical efficacy for the entire range of arrhythmia procedures performed in all four chambers of the heart. The new lab will be led by Dr. Sabine Ernst, Consultant Electrophysiologist and a pioneer in the application of magnetic navigation technology to electrophysiology.

"Through this installation we are continuing Royal Brompton and Harefield's long tradition of bringing the best possible medical care to our diverse patient population," said Dr. Ernst. "The Stereotaxis technology has emerged as the preferred therapeutic choice to treat a wide variety of arrhythmias. Magnetic navigation, combined with a very gentle catheter provides us with more precise catheter placement and allows us to access areas of the heart that may have been hard to reach utilizing other technologies or manual manipulation. As a result, patients with difficult to treat arrhythmias may find a successful resolution to their condition through a procedure performed on our new system."

"The installation of the combined Stereotaxis Niobe and Odyssey systems at the prestigious Royal Brompton Hospital represents another important milestone in establishing our technology in the leading hospitals of the world," said Bevil Hogg, CEO of Stereotaxis. "We believe our Stereotaxis Niobe system has demonstrated a peerless record of clinical safety, efficacy, and efficiency over more than 15,000 procedures, and now our Odyssey networked information management system is making it possible for physicians to better manage clinical workflows, archive procedures and is expected to play a critical role in the world wide dissemination of best practices."

Royal Brompton and Harefield NHS Trust is a national and international leader in the treatment of complex heart and lung conditions and is recognized for its contribution to cardiac research and advanced medicine. The hospital's adult congenital heart disease unit was the first of its kind in Europe and remains the largest. Royal Brompton acquired the United Kingdom's first dedicated cardiac CT scanner in 2005, and has the largest cardiac magnetic resonance center in the world.

### About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE Stereotaxis, Inc.

-0-

06/24/2008

/CONTACT: Company, Jim Stolze, Chief Financial Officer of Stereotaxis, Inc., +1-314-678-6105; or Investors, Doug Sherk & Jenifer Kirtland of EVC Group, Inc., +1-415-896-6820, or Media, Steve DiMattia & Chris Gale of EVC Group, Inc., +1-646-201-5445, both for Stereotaxis, Inc./

/Web site: <http://www.stereotaxis.com/>

(STXS)

CO: Stereotaxis, Inc.

ST: Missouri, England

IN: MTC HEA  
SU: PDT

CC-DT

-- AQTU083 --

7737 06/24/2008 09:00 EDT <http://www.prnewswire.com>